PANTHERx Selected by Rhythm Pharmaceuticals as Exclusive Pharmacy Partner for IMCIVREE
PANTHERx Rare Pharmacy announced that it was selected by Rhythm Pharmaceuticals as the exclusive U.S. Pharmacy distribution partner for the expanded indication of IMCIVREE for adults and children 4 years of age and older living with acquired hypothalamic obesity. "This new indication for IMCIVREE marks an important scientific milestone for individuals and families affected by acquired hypothalamic obesity, a highly complex disease with historically limited therapeutic options," said Bansi Nagji, CEO of PANTHERx Rare. "We're honored to deepen our collaboration with Rhythm Pharmaceuticals, and to help patients receive the personalized, high-touch clinical support necessary to navigate treatment." PANTHERx has been the exclusive pharmacy distribution partner for IMCIVREE for chronic weight management in adult and pediatric patients 2 years of age and older with obesity due to Bardet-Biedl Syndrome and proopiomelanocortin, proprotein convertase subtilisin/kexin type 1, or leptin receptor deficiency confirmed by genetic testing since 2020.
